Saxenda Recommended for Approval By a Board of FDA AdvisorsFriday, July 11, 2014

Another medication Sterling Research is studying has been
recommended for approval by a board of FDA advisors as a treatment for weight
management. Liraglutide is already FDA approved for the treatment of Diabetes Mellitus
Type 2. It goes by the brand name
Victoza.

When it is officially FDA
approved, the weight loss therapy will marketed as Saxenda. It will come as a 3mg dose, delivered
subcutaneously.

Obesity is reaching
epidemic proportions, and now patients worldwide will have another option in
the battle against this disease. Thanks to all of our medical heroes that made
this day possible!